Across TCGA pan-cancer cohorts, RN7SKP86 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RN7SKP86’s most consistent transcriptional readouts.
The strongest signal is observed in prostate adenocarcinoma (PRAD), where RN7SKP86 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RN7SKP86 is over-expressed in tumor.
PRAD and LUAD are the cancer types where RN7SKP86 tumor–normal differential expression is most reproducible.